US breakthrough order for Allenex with SBT Resolver™

A leading United States based HLA laboratory has chosen Allenex´s US
distribution company Olerup Inc as their partner for the delivery of sequence
based HLA tissue typing, SBT. This top tier immunogenetics laboratory has
evaluated and validated SBT Resolver™ from the Allenex partner Conexio Genomics.
The lab committed to the use of SBT Resolver™, and has already subsequently
placed an initial order, which also include the proprietary software Assign™
3.6+. Yearly sales are estimated at over two million SEK for 2013.

“This is a breakthrough event and a major step forward regarding our sales of
SBT Resolver™ for HLA typing for bone marrow transplants” says Anders Karlsson,
CEO of Allenex. ”We are happy and proud to be able to meet the expectations from
this top HLA laboratory. Timing wise this is very important since Olerup Inc is
currently working intensely with a number of other large US based typing
laboratories undergoing a similar evaluation process regarding choice of SBT
solutions” he concludes.

Allenex/Olerup Inc has effectively developed a positive US market presence, as
it grows its penetration among the 65 HLA laboratories that currently use SBT in
the US market. Allenex/Olerup and its partner Conexio Genomics will be the sole
source offering Assign™ software after December 31, 2013. Assign™ is the most
widely used software for SBT typing in the US and the latest version (3.6+) of
that software will only be offered to HLA laboratories as a part of the SBT
Resolver™ product solution.

The decision making process for this type of technology is relatively long,
between 6-18 months. An increasing number of US HLA laboratories are now in an
advanced stage of evaluating the SBT Resolver™ offering. Ten large US
laboratories are close to the end of the validation process, while more than ten
labs are in the early stages of evaluating SBT Resolver™. More laboratories have
committed to initiate the evaluation and validation process during 2013.
Allenex/Olerup believes that several of these will become new customers that
will utilize the SBT Resolver™ solution in the United States, thereby providing
the potential to positively impact bone marrow transplant outcomes.

For more information please contact:
Anders Karlsson, CEO Allenex AB, and ph.: +4670-918 00 10, e-mail:
anders.karlsson@allenex.se

Allenex AB discloses the information provided herein pursuant to the Securities
Markets Act and /or the Financial Instruments Trading Act. The information was
submitted for publication on Feb 19, 2013, at 11.15 CET. Allenex is a life
science-company that develops, manufacture, market and sell products for safer
transplants of organs and bone marrow on the global market. Allenex is listed on
NASDAQ OMX Stockholm Small Cap (ticker: ALNX). 52 persons are employed in the
Allenex group.